ArticleJournal of neuro-oncology2025
Fluorescence molecular imaging of high-grade gliomas and brain metastases using the RAS70 peptide targeting plasma membrane-bound Hsp70 on tumor cells.
Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Research progress in imaging detection of brain metastases.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOne of the promising targets for fluorescence-guided surgery of malignant brain tumors is a 70 kDa heat shock protein (mHsp70), which has been found on the plasma membrane of tumor cells. In this study, we conjugated the RAS70 peptide, which targets mHsp70 on tumor cells, with the fluorophore Cy7.5 and used it for epifluorescence detection of mHsp70-positive glial tumors and brain metastases.
methodsThe study included adult patients with newly diagnosed glioblastoma (GBL, n = 7) and brain metastases (MTS, n = 8). Three hours prior to surgery, patients received an oral solution of 5-aminolevulinic acid (5-ALA, 20 mg/kg). During surgery, tumor samples were obtained from three zones: necrotic, viable tumor, and perifocal. Some samples were treated ex vivo with the RAS70-Cy7.5 peptide, while others were treated with the control peptide NGL-RGD-Cy7.5. Epifluorescence images were obtained using an operating microscope in FL400 and FL800 modes, image analysis was performed in ImageJ with calculation of the target-to-background ratio (TBR). The presence of mHsp70 on the tumor cell membrane was additionally determined using immunofluorescence microscopy.
resultsImmunofluorescence staining revealed mHsp70-positive tumor cells in all studied samples, with preferential localization observed in the viable (contrast-enhancing) and perifocal tumor zones. TBRs for fluorescence imaging of RAS70-Cy7.5 peptide were significantly higher than those for the control peptide (p < 0.0001): necrotic zone 19.2 a.u. (15.5–21.0), viable tumor 9.0 a.u. (7.0–11.5), perifocal zone 8.9 a.u. (6.7–11.4), control – 1.2 a.u. (0.9–1.7). RAS70 exhibited 37.5% more visible fluorescence than 5-ALA in viable metastasis zones (p < 0.001). The RAS70 peptide was more sensitive and specific than 5-ALA for detecting perifocal zones in glioblastomas and brain metastases (100% vs. < 75% and 100% vs. < 85%, respectively).
conclusionThe RAS70 peptide demonstrated high diagnostic accuracy for glioblastoma and metastases, suggesting potential applications in intraoperative image-guided tumor resection and the development of targeted drug delivery systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.